Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid

被引:5
|
作者
Mallett, MS
Hagan, RL
Peters, DA
机构
[1] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,MORRIS PLAINS,NJ 07950
[2] DAVID GRANT MED CTR,DEPT PHARM,PHARM SUPPORT SERV,CLIN INVEST FACIL,TRAVIS AFB,CA
关键词
capsules; cholelitholytic agents; compounding; formulations; glycerin; incompatibilities; orange syrup; stability; storage; suspending agents; suspensions; sweetening agents; temperature; ursodiol; vehicles;
D O I
10.1093/ajhp/54.12.1401
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The stability of ursodiol in an extemporaneously formulated oral liquid was studied. A suspension was prepared by combining the contents of commercially available 300-mg capsules of ursodiol with glycerin, Ora-Plus (Paddock Laboratories), and orange syrup. A second formulation was prepared by combining ursodiol capsules with sterile water for irrigation. The final concentration of ursodiol in each formulation was 25 mg/mL. Six samples of each preparation were stored in 4-oz amber plastic prescription bottles protected from light. Three were stored at 22-23 degrees C and three were refrigerated al 2-6 degrees C. Immediately after preparation and at 7, 15, 30, 45, and 60 days, samples were obtained and frozen until assay by high-performance liquid chromatography. On day 60 the mean percentage of the initial ursodiol concentration remaining was 108.4% for the suspension stored at room temperature and 103.3% for the refrigerated suspension. The ursodiol-in-water formulation was not analyzed because of rapid settling of ursodiol. Ursodiol 25 mg/mL in an oral liquid prepared extemporaneously from capsules and sweetened vehicle was stable for 60 days when stored in amber plastic bottles at 22-23 and 2-6 degrees C. Addition of ursodiol powder to water without a suspending agent resulted in a liquid formulation with a high variability in content uniformity.
引用
收藏
页码:1401 / 1404
页数:4
相关论文
共 50 条
  • [21] Stability of extemporaneously prepared oxandrolone oral suspensions
    Johnson, Cary E.
    Cober, Mary Petrea
    Hawkins, Katherine A.
    Julian, Justin D.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (06) : 519 - 521
  • [22] Stability of an extemporaneously prepared clopidogrel oral suspension
    Skillman, Katherine L.
    Caruthers, Regine L.
    Johnson, Cary E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (07) : 559 - 561
  • [23] Stability of famotidine in an extemporaneously compounded oral liquid
    Dentinger, PJ
    Swenson, CF
    Anaizi, NM
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (14) : 1340 - 1342
  • [24] Stability of sumatriptan succinate in extemporaneously prepared oral liquids
    Fish, DN
    Beall, HD
    Goodwin, SD
    Fox, JL
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (14) : 1619 - 1622
  • [25] STABILITY OF ATENOLOL IN AN EXTEMPORANEOUSLY COMPOUNDED ORAL LIQUID
    GARNER, SS
    WIEST, DB
    REYNOLDS, ER
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1994, 51 (04): : 508 - 511
  • [26] Stability of flucytosine in an extemporaneously compounded oral liquid
    Wintermeyer, SM
    Nahata, MC
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (04) : 407 - 409
  • [27] Stability of tacrolimus in an extemporaneously compounded oral liquid
    Jacobson, PA
    Johnson, CE
    West, NJ
    Foster, JA
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (02) : 178 - 180
  • [28] STABILITY OF ITRACONAZOLE IN AN EXTEMPORANEOUSLY COMPOUNDED ORAL LIQUID
    JACOBSON, PA
    JOHNSON, CE
    WALTERS, JR
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (02) : 189 - 191
  • [29] Stability of valganciclovir in an extemporaneously compounded oral liquid
    Anaizi, NH
    Dentinger, PJ
    Swenson, CF
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (13) : 1267 - 1270
  • [30] STABILITY OF ISRADIPINE IN AN EXTEMPORANEOUSLY COMPOUNDED ORAL LIQUID
    MACDONALD, JL
    JOHNSON, CE
    JACOBSON, P
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1994, 51 (19): : 2409 - 2411